HS 10241
Alternative Names: HS-10241Latest Information Update: 28 Feb 2025
At a glance
- Originator Jiangsu Hengrui Medicine Co.
- Class Antineoplastics
- Mechanism of Action Proto-oncogene protein c-met inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Non-small cell lung cancer; Solid tumours
Most Recent Events
- 28 Feb 2025 No recent reports of development identified for phase-I development in Non-small-cell-lung-cancer(Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in China (PO)
- 12 Feb 2025 Jiangsu Hansoh Pharmaceutical plans a phase I pharmacokinetic trial in February 2025 (PO) (NCT06823245)
- 01 Nov 2023 Jiangsu Hansoh Pharmaceutical plans a phase III trial for Non-small cell lung cancer (Combination therapy, Second-line therapy or greater, Metastatic disease, Late-stage disease) (PO) in December 2023 (NCT06110663)